gs ▁class ified ▁as ▁" AX L ▁in hib itors " ▁have ▁entered ▁clin ical ▁tri als ; ▁however , ▁many ▁target ▁multiple ▁kin ase ▁re cept ors ▁in ▁addition ▁to ▁A X L . ▁The ▁most ▁advanced ▁A X L ▁select ive ▁in hib itor ▁is ▁bem cent in ib ▁( B GB 3 2 4 ▁or ▁R 4 2 8 ), ▁an ▁or al ▁small ▁mole c ule ▁currently ▁in ▁multiple ▁Ph ase ▁II ▁clin ical ▁tri als ▁for ▁NS CLC , ▁T N BC , ▁A ML ▁and ▁mel an oma . ▁B em cent in ib ▁is ▁being ▁purs ued ▁as ▁mon other apy ▁and ▁as ▁combination ▁ther apy ▁with ▁existing ▁and ▁emer ging ▁target ed ▁ther ap ies , ▁imm un other ap ies ▁and ▁chem other apy . ▁ ▁A ▁mon oc l onal ▁ant ib ody ▁target ing ▁A X L ▁( Y W 3 2 7 . 6 S 2 ) ▁and ▁an ▁A X L ▁de co y ▁re ceptor ▁( GL 2 I . T ) ▁are ▁currently ▁in ▁pre cl in ical ▁development . ▁Additionally , ▁an ▁or al ▁A X L ▁in hib itor ▁( TP - 0 9 0 3 ) ▁is ▁expected ▁to ▁enter ▁Ph ase ▁ 1 ▁clin ical ▁trial ▁in ▁November ▁ 2 0 1 6 ▁( in ▁advanced ▁solid ▁tum ours : ▁N CT 0 2 7 2 9 2 9 8 ). ▁ ▁Non - select ive ▁A X L ▁in hib itors ▁in ▁clin